Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
11:06am, Thursday, 30'th Jul 2026
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
04:05pm, Thursday, 23'rd Jul 2026
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most p
Prime Medicine, Inc. $PRME Shares Sold by Amova Asset Management Americas Inc.
03:16am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. lessened its position in Prime Medicine, Inc. (NASDAQ: PRME) by 9.4% during the undefined quarter, according to its most recent filing with the Securities and Exch
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
10:22am, Thursday, 09'th Jul 2026
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers p
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
01:29pm, Wednesday, 08'th Jul 2026
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
08:00am, Wednesday, 08'th Jul 2026
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary d
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in p4
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
08:00am, Thursday, 18'th Jun 2026
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North Ameri
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
04:10pm, Monday, 15'th Jun 2026
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DNA technology to search and replace genetic mutati
Prime Medicine's Prime Editing Is Worth The Risk
04:51am, Saturday, 13'th Jun 2026
Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: Prime Editing. PM359 was essentially their most advanced application of Prime Editing, even though CG
Prime Drink Group Announces Private Placement and Agreed Resolution with Creditors
06:30pm, Friday, 12'th Jun 2026
MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of uni
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
03:12pm, Wednesday, 10'th Jun 2026
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
04:12pm, Friday, 05'th Jun 2026
Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
08:00am, Wednesday, 03'rd Jun 2026
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine to Present at Jefferies Global Healthcare Conference
08:00am, Thursday, 28'th May 2026
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
